Condition: Sickle Cell Disease · Sponsor: Novo Nordisk A/S
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.
This description comes directly from the study's public registry record.
Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
Always discuss trial participation with your own doctor first.
| Uni of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Univer South Alabama Ped/Onc | Mobile, Alabama, United States | Recruiting |
| Phoenix Children's Hsptl | Phoenix, Arizona, United States | Recruiting |
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | Recruiting |
| Children's Hospital Los Angeles - Endocrinology | Los Angeles, California, United States | Recruiting |
| UCLA Health | Los Angeles, California, United States | Recruiting |
| Valley Children's Hospital | Madera, California, United States | Recruiting |
| University Of California Irvine | Orange, California, United States | Completed |
| Stanford University_Palo Alto | Palo Alto, California, United States | Recruiting |
| Harbor-UCLA Medical Center | Torrance, California, United States | Recruiting |
| Clinical and Transl Res Center | Aurora, Colorado, United States | Completed |
| Nemours/AI duPont Hosp-Chld | Wilmington, Delaware, United States | Recruiting |
+ 162 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06612268